Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

被引：0
|
作者：
Vipul Kumar
Edgar L. Schuck
Robert D. Pelletier
Nadia Farah
Krista B. Condon
Meng Ye
Christopher Rowbottom
Belinda M. King
Zhi-Yi Zhang
Philip L. Saxton
Y. Nancy Wong
机构：
[1] Cubist Pharmaceuticals,Non
[2] Biopharmaceutical Assessments CFU,clinical Drug Development
[3] Eisai Inc.,DMPK
[4] Eisai Inc.,Andover
[5] Biogen Idec,Development Quality Assurance
[6] 14 Cambridge Center,Department of Drug Metabolism and Pharmacokinetics
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
E6201; Pharmacokinetics; MEK1 inhibitor; Protein binding; CYP induction; CYP inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 237
页数：8
相关论文
共 30 条
  • [11] CTC BIOMARKER ASSESSMENT TO AID DOSING SELECTION OF E6201, A POTENTIAL MEK1 INHIBITOR, FOR TREATMENT OF BRAF-MUTATED MELANOMA
    Eisen, A.
    Akerele, C.
    Reyderman, L.
    Verbel, D. A.
    Simon, J. S.
    Davis, D. W.
    Nomoto, K.
    Wang, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 405 - 405
  • [12] E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases
    Babiker, Hani M.
    Byron, Sara A.
    Hendricks, William P. D.
    Elmquist, William F.
    Gampa, Gautham
    Vondrak, Jessica
    Aldrich, Jessica
    Cuyugan, Lori
    Adkins, Jonathan
    De Luca, Valerie
    Tibes, Raoul
    Borad, Mitesh J.
    Marceau, Katie
    Myers, Thomas J.
    Paradiso, Linda J.
    Liang, Winnie S.
    Korn, Ronald L.
    Cridebring, Derek
    Von Hoff, Daniel D.
    Carpten, John D.
    Craig, David W.
    Trent, Jeffrey M.
    Gordon, Michael S.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 636 - 645
  • [13] E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases
    Hani M. Babiker
    Sara A. Byron
    William P. D. Hendricks
    William F. Elmquist
    Gautham Gampa
    Jessica Vondrak
    Jessica Aldrich
    Lori Cuyugan
    Jonathan Adkins
    Valerie De Luca
    Raoul Tibes
    Mitesh J. Borad
    Katie Marceau
    Thomas J. Myers
    Linda J. Paradiso
    Winnie S. Liang
    Ronald L. Korn
    Derek Cridebring
    Daniel D. Von Hoff
    John D. Carpten
    David W. Craig
    Jeffrey M. Trent
    Michael S. Gordon
    Investigational New Drugs, 2019, 37 : 636 - 645
  • [14] Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
    Narita, Yusuke
    Okamoto, Kiyoshi
    Kawada, Megumi Ikemori
    Takase, Kazuma
    Minoshima, Yukinori
    Kodama, Kotaro
    Iwata, Masao
    Miyamoto, Norimasa
    Sawada, Kohei
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (04) : 823 - 832
  • [15] Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer (vol 175, pg 339, 2019)
    Lee, Jangsoon
    Lim, Bora
    Pearson, Troy
    Choi, Kuicheon
    Fuson, Jon A.
    Bartholomeusz, Chandra
    Paradiso, Linda J.
    Myers, Thomas
    Tripathy, Debu
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (01) : 251 - 251
  • [16] Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors
    Borad, M. J.
    Akerele, C. E.
    Ramanathan, R. K.
    Northfelt, D. W.
    Reyderman, L.
    Verbel, D.
    Feit, K.
    Von Hoff, D. D.
    Tibes, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [17] Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1
    Lee, Ki Won
    Kang, Nam Joo
    Rogozin, Evgeny A.
    Kim, Hong-Gyum
    Cho, Yong Yeon
    Bode, Ann M.
    Lee, Hyong Joo
    Surh, Young-Joon
    Bowden, G. Tim
    Dong, Zigang
    CARCINOGENESIS, 2007, 28 (09) : 1918 - 1927
  • [18] Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation.
    Narita, Yusuke
    Okamoto, Kiyoshi
    Kawada, Megumi Ikemori
    Takase, Kazuma
    Minoshima, Yukinori
    Kodama, Kotaro
    Iwata, Masao
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [19] Characterization of GSK1120212 a novel allosteric inhibitor of MEK1/2
    Erskine, S.
    Rominger, C.
    Zappacosta, F.
    Laquerre, S.
    Adams, J.
    Tummino, P.
    Lai, Z.
    EJC SUPPLEMENTS, 2008, 6 (12): : 44 - 45
  • [20] Dual inhibitor of ACVR1 and MEK 1/2 E6201 and PI3K/mTOR inhibitor paxalisib synergistically inhibit cell growth in DMG
    Kwon, Hyuk Jean
    Tindall, Abigail
    Eberhart, Charles
    Rubens, Jeffrey
    Raabe, Eric
    CANCER RESEARCH, 2023, 83 (07)
123